Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections

• Status: Not yet recruiting
• Trial end date: 2024-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical trial is to learn about the benefit of IVIG in donor-derived infections and the potential immunomodulatory effect on transplanted organs. The main questions it aims to answer are:

1. How effective IVIG is in preventing donor-derived infections

2. Does IVIG has potential immunomodulatory effect on transplanted organs

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Changzheng Hospital

Criteria

Inclusion Criteria:

• Any person approved as a transplant donor with recipient who has never undergone a previous transplantation

• Transplant donor must be 6 years old or older

• They must have provided signed informed consent

• The donors must be willing to contribute samples of blood

Exclusion Criteria:

• Any potential transplant donor who is receiving or have received anti-herpes medication in the past week

• Any potential transplant donor to a recipient who has received a previous solid organ transplant

• Any potential transplant donor who is immunosuppressed due to medical disease and/or immunosuppressive or immunomodulating medications

• Any potential transplant donor who is on corticosteroids